NCT01616589Unknown不适用
Acquisition of Saliva Samples for Validation as a Specimen Type in the Esoterix Genetic Laboratories Fragile X Assay
适应症
试验速览
- 阶段
- 不适用
- 入组人数
- 100
- 试验地点
- 1
研究概览
简要总结
The purpose of this research is to determine if saliva samples can be used as an alternate sample type to test for fragile X. By using saliva instead of blood, it would be easier for patients to have fragile X testing.
详细描述
Saliva samples will be prospectively collected from subjects who have previously been tested by Esoterix Genetic Laboratories, LLC using blood specimens and diagnosed as fragile X intermediates, premutations (carriers) or full mutations (affected). Results from fragile X testing with saliva will be compared to results from the blood sample that was previously submitted to Esoterix Genetic Laboratories for testing.
Data from this study will be used for regulatory submissions.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subject has previously been identified through molecular testing at Esoterix Genetic Laboratories as a Fragile X intermediate, premutation (carrier) or full mutation (affected).
- •In the opinion of the subject's physician, the subject is medically stable and able to provide the required quantity of saliva.
- •If Subject is at least 18 years of age:
- •Subject must be willing to give written informed consent
- •Subject must be willing to comply with the collection procedure
- •If Subject is under 18 years of age, the legally authorized representative must give written informed consent and agree to comply with study procedures.
排除标准
- •Subject has been determined to be an individual with a normal FMR1 gene.
- •Subject has a known medical condition that would cause risk to the donor or, if relevant, the fetus as a result of saliva collection.
研究者
研究点 (1)
Loading locations...
相似试验
已完成
Unknown
Application of saliva markers for the in vivo testing of dosage formsDetermination of the gastric residence time of a new formulation compared to an established formulationDRKS00031999Institut für Pharmazie - Biopharmazie & Pharmazeutische Technologie12
已完成
不适用
COVID-19 and SARS-CoV-2 Detection in SalivaRNA Virus InfectionsNCT04517682Ambry Genetics67
已完成
不适用
Self-Collected Saliva Samples Without Viral Transport Media for COVID-19 Testing Via RT-PCRSARS-CoV InfectionPolymerase Chain ReactionLaboratory TestingNCT04604145David Grant U.S. Air Force Medical Center60
终止
不适用
Inpatient COVID-19 Lollipop StudyCOVID-19Diagnostic TestNCT05801341University of Wisconsin, Madison17
Unknown
不适用
Antiviral Activity of Oral ProbioticsUpper Respiratory Tract InfectionLower Respiratory Tract InfectionNCT05374070John Hale20